EGFR and cancer: The 12 major dominant differential metabolite components of CJ were also predicted as targets using the network pharmacology method, and the results revealed that they primarily involved 229 targets, including PIK3CA, PIK3R1, HSP90AA1, EGFR, MAPK1, etc., and the targets were enriched in 147 pathways, including Nitrogen metabolism, Prostate cancer, HIF-1 signaling pathway, and proteoglycans in cancer.